Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.77 |
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.77 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.74 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444024 | 1.00 | CYSLTR1 (0.77) | CYSLTR1CYSLTR2GPBAR1FFAR1AKR1B1 | |
| SCHEMBL30443831 | 0.98 | CYSLTR1 (0.81) | CYSLTR1CYSLTR2GPBAR1FFAR1AKR1B1 | |
| SCHEMBL25244522 | 0.98 | CYSLTR1 (0.81) | CYSLTR1CYSLTR2GPBAR1FFAR1AKR1B1 | |
| SCHEMBL26632679 | 0.87 | GPBAR1 (0.76) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL30443642 | 0.87 | GPBAR1 (0.76) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL14021495 | 0.87 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2GPBAR1FFAR1AKR1B1 | |
| SCHEMBL30443485 | 0.86 | GPBAR1 (1.00) | CYSLTR1CYSLTR2GPBAR1FFAR1AKR1B1 | |
| SCHEMBL25260279 | 0.86 | GPBAR1 (1.00) | CYSLTR1CYSLTR2GPBAR1FFAR1AKR1B1 | |
| SCHEMBL10545819 | 0.86 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2GPBAR1FFAR1AKR1B1 | |
| SCHEMBL10638728 | 0.83 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1FFAR1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | PREC BIO THERAPEUTICS S R L (IT) | 2023-11-09 | — | — | US | disclosed |
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | PREC BIO THERAPEUTICS S R L (IT) | 2023-11-09 | — | — | US | disclosed |
| CN-116323560-A | Quinoline compounds as selective and/or dual modulators of bile acid receptors and leukotriene cysteinyl receptors | 精密生物治疗有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4192815-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | Precision Bio-Therapeutics S.r.l. (IT) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | GPBAR1, CYSLTR1, CYSLTR2 | CYSLTR1 2/4885CYSLTR2 3/4885GPBAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.